TABLE 2.

MIC range, MIC₅₀ and MIC₉₀ of cefepime/zidebactam and other antibiotics for all P. aeruginosa (n = 108)

Antibiotic/combinations	MIC (mg/L)			% Susceptibilitya
	MIC50	MIC90	Range
Cefepime	32	≥128	1 - ≥ 128	25.9
Cefepime/zidebactam	4	16	0.5–32	86.1b / 100c
Cefepime/taniborbactam	16	≥128	1 - ≥ 128	43.5b
Ceftolozane/tazobactam	16	≥128	0.12 - ≥ 128	38.9
Ceftazidime/avibactam	16	≥128	0.5 - ≥ 128	44.4
Aztreonam/avibactam	32	≥128	0.25 - ≥ 128	23.1d
Imipenem	32	≥128	0.12 - ≥ 128	9.3
Imipenem/relebactam	4	≥128	0.12 ≥ 128	45.4
Meropenem	32	≥128	0.5 - ≥ 128	5.6
Meropenem/vaborbactam	16	≥128	0.25 - ≥ 128	33.3e
Ciprofloxacin	16	≥128	0.06 - ≥ 128	12
Amikacin	16	≥128	0.25 - ≥ 128	56.5
Colistin	≤0.25	1	0.03 - ≥ 128	94.4f

^a Susceptibility interpreted against FDA criteria.

^b As per cefepime susceptible breakpoint.

^c As per cefepime/zidebactam’s proposed PK/PD breakpoint of ≤32 mg/L.

^d As per aztreonam standalone susceptibility breakpoint.

^e Based on meropenem susceptible breakpoint of ≤2 mg/L.

^f Based on CLSI intermediate breakpoint of ≤2 mg/L.